L3VLUP
ProSign in

HAE · VRTX in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

HAEVRTX
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • HAE
  • VRTX
010203040202120222023202420252026
Holders and value by quarter
QuarterHAEVRTX
Q3 202016 holders, $1.3bn31 holders, $21.9bn
Q4 202011 holders, $1.6bn30 holders, $18.4bn
Q1 202111 holders, $1.5bn31 holders, $15.4bn
Q2 20218 holders, $741m30 holders, $12.7bn
Q3 202111 holders, $843m35 holders, $10.1bn
Q4 202110 holders, $649m28 holders, $12.4bn
Q1 20229 holders, $1.0bn23 holders, $16.1bn
Q2 20228 holders, $1.1bn25 holders, $18.1bn
Q3 20228 holders, $1.3bn22 holders, $18.4bn
Q4 20228 holders, $1.2bn28 holders, $18.4bn
Q1 20237 holders, $1.2bn26 holders, $21.4bn
Q2 20237 holders, $1.2bn27 holders, $24.7bn
Q3 20237 holders, $1.2bn33 holders, $24.3bn
Q4 20236 holders, $1.2bn32 holders, $28.6bn
Q1 20246 holders, $1.3bn31 holders, $29.8bn
Q2 20245 holders, $1.2bn29 holders, $33.4bn
Q3 20245 holders, $1.0bn27 holders, $33.5bn
Q4 20245 holders, $986m26 holders, $28.5bn
Q1 20259 holders, $622m21 holders, $35.4bn
Q2 20259 holders, $666m21 holders, $32.3bn
Q3 20255 holders, $323m22 holders, $25.9bn
Q4 20258 holders, $894m26 holders, $31.8bn
Q1 20263 holders, $464m25 holders, $31.8bn
Q2 20266 holders, $619m26 holders, $34.6bn
HAE

Haemonetics Corp Mass

Holders
6
Reported value
$619m
Buyers
12
Sellers
18

Breadth -6 among 91 comparable managers.

Medical devices and instrumentsHealthcare: biopharma and medtech · L3VLUPSurgical, medical and electromedical devices
VRTX

Vertex Pharmaceuticals Inc

Holders
26
Reported value
$34.6bn
Buyers
21
Sellers
17

Breadth +4 among 91 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q2 2026

Among the 27 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only HAE (1)

Verition Fund Management LLC

Only VRTX (21)

Acadian Asset Management LLC, AllianceBernstein LP, Baillie Gifford & Co, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Fidelity (FMR LLC), Hudson Bay Capital Management LP, Invesco Ltd, Janus Henderson Group Ltd, Man Group PLC, Marshall Wace LLP, MFS Investment Management, Millennium Management LLC, Renaissance Technologies LLC, T. Rowe Price Associates Inc, Two Sigma Investments LP, Wellington Management Group LLP, Woodline Partners LP

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →